Imaging Plaque Inflammation in Higher-Risk Patients: What Do We Know and What Are We Looking For?

被引：0
作者：
Ishai A. [1 ]
Tawakol A. [1 ,2 ]
机构：
[1] Cardiac MR PET CT Program, Department of Imaging, Massachusetts General Hospital and Harvard Medical School Boston, 165 Cambridge Street, Suite 400, Boston, 02114-2750, MA
[2] Cardiology Division, Massachusetts General Hospital and Harvard Medical School Boston, 165 Cambridge Street, Suite 400, Boston, 02114-2750, MA
来源：
Current Cardiovascular Risk Reports | 2015年 / 9卷 / 6期
关键词：
Atherosclerosis; FDG-PET; Inflammation;
D O I：
10.1007/s12170-015-0459-0
中图分类号：
学科分类号：
摘要：
Atherosclerosis is a chronic inflammatory condition complicating cholesterol accumulation within the artery wall. Inflammation is believed to play an important role in the formation, progression, and ultimately the rupture of atherosclerotic plaques (the principle event leading to most myocardial infarctions and strokes). An enhanced understanding of the inflammatory process within the atheroma may therefore facilitate risk stratification and treatment strategies. Molecular imaging techniques such as PET/CT have the ability to quantify arterial inflammation and assess the high-risk features of atheromas thus may be useful for identifying patients who are at higher risk for an atherothrombotic event. In this review, we focus on the potential of FDG-PET/CT as a tool to measure arterial inflammation, enhance risk stratification, and to evaluate novel therapies directed against atherosclerotic disease. Additionally, this review will provide a discussion on current challenges as well as future directions. © 2015, Springer Science+Business Media New York.
引用
收藏
页码：1 / 8
页数：7
相关论文
共 65 条
  • [51] Erdmann E., Dormandy J.A., Charbonnel B., Massi-Benedetti M., Moules I.K., Skene A.M., Et al., The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study, J Am Coll Cardiol, 49, 17, pp. 1772-1780, (2007)
  • [52] Schwartz G.G., Olsson A.G., Abt M., Ballantyne C.M., Barter P.J., Brumm J., Et al., Effects of dalcetrapib in patients with a recent acute coronary syndrome, N Engl J Med, 367, 22, pp. 2089-2099, (2012)
  • [53] Tawakol A., Singh P., Rudd J.H., Soffer J., Cai G., Vucic E., Et al., Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging, J Am Coll Cardiol, 63, 1, pp. 86-88, (2014)
  • [54] Investigators S., White H.D., Held C., Stewart R., Tarka E., Brown R., Et al., Darapladib for preventing ischemic events in stable coronary heart disease, N Engl J Med, 370, 18, pp. 1702-1711, (2014)
  • [55] O'Donoghue M.L., Braunwald E., White H.D., Lukas M.A., Tarka E., Steg P.G., Et al., Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial, Jama, 312, 10, pp. 1006-1015, (2014)
  • [56] Cheng V.Y., Slomka P.J., Le Meunier L., Tamarappoo B.K., Nakazato R., Dey D., Et al., Coronary arterial 18F-FDG uptake by fusion of PET and coronary CT angiography at sites of percutaneous stenting for acute myocardial infarction and stable coronary artery disease, J Nucl Med Off Publ Soc Nucl Med, 53, 4, pp. 575-583, (2012)
  • [57] Wykrzykowska J., Lehman S., Williams G., Parker J.A., Palmer M.R., Varkey S., Et al., Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation, J Nucl Med Off Publ Soc Nucl Med, 50, 4, pp. 563-568, (2009)
  • [58] Rudd J.H., Narula J., Strauss H.W., Virmani R., Machac J., Klimas M., Et al., Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time?, J Am Coll Cardiol, 55, 23, pp. 2527-2535, (2010)
  • [59] Rogers I.S., Nasir K., Figueroa A.L., Cury R.C., Hoffmann U., Vermylen D.A., Et al., Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina, J Am Coll Cardiol Img, 3, 4, pp. 388-397, (2010)
  • [60] Dweck M.R., Chow M.W., Joshi N.V., Williams M.C., Jones C., Fletcher A.M., Et al., Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology, J Am Coll Cardiol, 59, 17, pp. 1539-1548, (2012)
1234567